Search PubMed⌕ Search

Biomedical subjects

B Coiffier

Publications and source records attributed to B Coiffier.

261 records · Page 15Linked to original sources
PubMedDate not supplied

[Treatment of aggressive primary lymphomas of the digestive system by intensive chemotherapy. Experience of the Study Group on Lymphomas in Adults with the LNH-84 protocol].

Ninety-one patients with primary gastrointestinal lymphoma included in the LNH-84 multicentric regimen were analyzed to determine the efficacy and the toxicity of intensive combination chemotherapy and of surgical debulking. All these patients had aggressive histological subtypes: 56 patients had localize disease, stage IE or IIE, and 35 patients had stage IV disease; 40 patients had bulky disease. Specific sites included stomach (43 cases), small bowel (35), ileo-cecum (13), colon (10), and rectum (6). Although 71 patients (78%) had an attempted surgical resection, only 28 (31%) had complete tumor excision. Patients were treated with 3 or 4 cycles of ACVB chemotherapy followed by sequential consolidation. Nine patients died during chemotherapy. With a median follow-up of 3 years, 10 patients have relapsed and predicted 4-year survival of the entire group is 62%. In stage IE or IIE patients, survival and disease-free survival are similar in patients who underwent complete resection or incomplete or no surgical resection prior to the administration of chemotherapy. Prognostic factors predicting for survival were similar to the entire group of patients treated with the LNH-84 regimen. Aggressive gastrointestinal lymphoma patients treated with intensive chemotherapy have outcome and prognostic factors comparable to those of other similarly staged aggressive lymphoma patients. Surgical resection prior to the administration of combination chemotherapy did not influence survival or disease-free survival in patients with localized disease.

Adolescent↗
PubMedDate not supplied

[Treatment of 100 acute myeloid leukemias (author's transl)].

Between november 1974 and august 1976, 100 acute myeloïd leukemias were treated by the same protocol L. 275. Induction treatment was daunorubicine, vincristine, cytosine arabinoside, in one intensive course for patients under 65 and cyclophosphamide (CPM), VCR and CAR in a less intensive and repetitive courses for patients over 65. In remission, there were three phases: consolidation, prevention of central nervous system leukemia, maintenance. All patients in remission received an androgenotherapy and two groups were randomised: chemotherapy and chemotherapy plus BCG. 68 patients were in complet remission (CR) 61 out of 80 patients under 65 and 7 out of 20 over 65. Median duration of first remission was 12 months. Median duration of survival was 13 months for all patients, 15 months for patients under 65, 3 months for patients over 65, and 22 months for 68 patients in CR. Survival of patients receiving BCG was slightly better than patients without BCG.

Adolescent↗
PubMedDate not supplied

Delayed hypersensitivity skin reactions in the induction phase of remission in acute non lymphoid leukemias.

Delayed skin reactions to Tuberculin (10 units, intradermal) and Candidin (1:1000, intra dermal) were studies in a homogenous group of 41 patients with acute non lymphoid leukemias in their initial phase. Remission-rate is higher in non-anergic patients (63%) than in anergic patients (32%), (p less than 0.05). Death-rate (within 30 days after chemotherapy) is higher in anergic patients (50%) than in non-anergic patients (16%), (p less than 0.05). There is no correlation between delayed skin reactions and age, initial absolute counts of neutrophil-lymphocyte-monocyte-blast cells, and results of humoral immunity. Delayed skin reactions are interesting in defining a high-risk group in the induction phase of remission of acute non lymphoid leukemias.

Acute Disease↗
PubMedDate not supplied

Chronic granulocytic leukemia : early detection of metamorphosis with "in vitro" culture of granulocytic progenitors.

The study of bone marrow granulocytic precursors (GM CFU-C) has been made in patients with a chronic granulocytic leukemia (CGL), at diagnosis and during the evolution. In vitro growth was increased with a normal clusters/colonies ratio in 17 patients, 2 have presented a metamorphosis. In vitro growth was abnormal in 30 patients, 22 have presented a metamorphosis with a median of 9 months after the in vitro study. The in vitro growth of GM CFU-C in CGL patients could detect the metamorphosis.

Bone Marrow Cells↗
PubMedDate not supplied

Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.

In the past few years, a number of experimental observations have provided more insight into the mechanisms of action of tumor necrosis factor (TNF)/lymphotoxin (LT) ligand-receptor system. This system consists of three ligands, TNF, LT alpha (LT alpha) and LT beta (LT beta), and three membrane-associated receptors, p55, p75 and LT beta-receptor (LT beta-R). Like TNF, LT alpha is a secreted protein which in solution forms a homotrimer molecule, with a conformation similar to that of TNF. LT beta is a transmembrane protein that provides the membrane anchor for the attachment to the cell surface of the heteromeric complex of LT alpha and LT beta. This complex retains a structure related to TNF and LT alpha homotrimers, with the homology regions interacting in a heterotypic fashion. The LT alpha 1:LT beta 2 heteromer has been found to be a predominant form of surface LT. The biological effects of TNF and LT alpha homotrimers are mediated by p55 and p75 receptors, while the heteromeric complex of LT alpha/LT beta transduces its cellular signal via LT beta-R. Membrane-associated receptor affinities as well as final biological effects of TNF/LT can be modulated by the influence of naturally occurring soluble receptors, derived from the cell surface by proteolytic cleavage. The multimerization of receptor cytoplasmic domains upon TNF/LT ligation is postulated to activate the intracellular signal-transduction pathways. One of them is the activation of phospholipase A2 (PL-A2) resulting in the production of arachidonic acid (AA) and other metabolites, including leukotriens, phosphatidycholine-specific phospholipase C (PC-PLC) with subsequent production of diacylglycerol (DAG) and activation of protein kinase C (PKC). As a third signaling pathway, TNF/LT employ the sphingomyelinase (SMase)-mediated hydrolysis of membrane sphingomyelin (SM) to ceramide. The final link in the TNF/LT signaling is activation of nuclear transcription factors, such as NF-kappa B, AP-1, interferon regulatory factors-1 and -2 (IRF-1, IRF-2), and NF-GMa. Since induction of AP-1, IRF-1 and IRF-2 as well as NF-GMa proceeds through translational event, the posttranslational TNF/LT-driven activation of NF-kappa B remains the only cellular event identified so far that serves as a direct target in their signaling cascade.

Animals↗